Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 43,156 shares traded.
Mateon Therapeutics Stock Performance
The firm’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- EV Stocks and How to Profit from Them
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- How to Use the MarketBeat Excel Dividend Calculator
- 2 Drone Stocks Surging from Increased Media Attention
- Best Stocks Under $10.00
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
